GTBP — GT Biopharma, Inc.
Is GTBP overbought or oversold? Here is the current MarketMoodz read.
GT Biopharma, Inc. (GTBP) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $6.10. The rating moved from Oversold to Strong Oversold on October 1, 2026.
- Public ratingStrong Oversold (as of October 3, 2026)
- Last close$6.10
- Last changeMoved from Oversold to Strong Oversold on October 1, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
GT Biopharma, Inc. (GTBP) is a small-cap, clinical-stage biopharma whose value is largely driven by pipeline milestones and financing dynamics. Visibility is limited by sparse recent filings and social sentiment data, so outcomes will be binary: favorable trial/regulatory developments and non-dilutive financing could deliver meaningful upside, whereas clinical setbacks, funding needs, or adverse payer actions could materially reduce valuation.
Key factors
- Clinical-stage small-cap biotech profile with pipeline-driven valuation; near-term data or partnership events could be meaningful catalysts.
- Market risk-off tone and light volumes reduce probability of strong directional moves absent company-specific news.
- Policy pressure on drug pricing (Medicare negotiation / IRA) increases reimbursement uncertainty for specialty therapies.
- Positive readthroughs in late-stage biologics in the sector support investor appetite for durable, tolerable rare‑disease or specialty oncology outcomes.
- Limited publicly available recent filings and social sentiment data constrain visibility into cash runway and operational execution.
- Sector dynamics: IPO cooling and capital markets softness could make fundraising more dilutive and costly if additional capital is required.
Risks
- Clinical trial setbacks or negative data that would directly depress an early-stage valuation.
- Need to raise capital in a tight market, leading to significant dilution for existing shareholders.
- Reimbursement and pricing pressure from Medicare negotiations and payer scrutiny, reducing potential commercial upside.
- Competitive pressures from larger biopharma entrants or alternative therapeutic modalities.
- Low liquidity and trading volume, increasing price volatility and bid/ask impact on execution.
- Regulatory delays or manufacturing/supply challenges that push timelines and increase costs.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for GTBP — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.